



US008846618B2

(12) **United States Patent**  
**Flink et al.**

(10) **Patent No.:** **US 8,846,618 B2**  
(45) **Date of Patent:** **Sep. 30, 2014**

(54) **STABLE FORMULATION OF MODIFIED GLP-1**

(75) Inventors: **James M. Flink**, Klanpenborg (DK); **Silke Møller Larsen**, Charlottenlund (DK); **Simon Bjerregaard Jensen**, Frederiksberg (DK); **Dorthe Kot Englund**, Holte (DK)

(73) Assignee: **Novo Nordisk A/S**, Bagsvaerd (DK)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/785,861**

(22) Filed: **May 24, 2010**

(65) **Prior Publication Data**

US 2010/0234299 A1 Sep. 16, 2010

**Related U.S. Application Data**

(63) Continuation of application No. 11/786,095, filed on Apr. 11, 2007, now abandoned, which is a continuation of application No. 10/185,923, filed on Jun. 27, 2002, now abandoned.

(60) Provisional application No. 60/308,325, filed on Jul. 27, 2001, provisional application No. 60/308,297, filed on Jul. 27, 2001.

(30) **Foreign Application Priority Data**

Jun. 28, 2001 (DK) ..... 2001 01010  
Jun. 28, 2001 (DK) ..... 2001 01011  
Jul. 4, 2001 (DK) ..... 2001 01052  
Jul. 4, 2001 (DK) ..... 2001 01053  
Jan. 18, 2002 (DK) ..... 2002 00093

(51) **Int. Cl.**

**A61K 38/26** (2006.01)  
**A61P 3/10** (2006.01)  
**A61P 7/12** (2006.01)  
**C07K 14/605** (2006.01)

(52) **U.S. Cl.**

CPC ..... **C07K 14/605** (2013.01);  
**A61K 38/26** (2013.01)  
USPC ..... **514/11.7**

(58) **Field of Classification Search**

CPC ..... A61K 38/26; C07K 14/605  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,468,346 A 8/1984 Paul et al.  
4,483,849 A 11/1984 Carter et al.  
5,206,219 A 4/1993 Desai  
5,272,135 A 12/1993 Takruri  
5,455,331 A 10/1995 Pearce  
5,652,216 A 7/1997 Kornfelt et al.

6,184,201 B1 2/2001 Drucker et al.  
6,245,572 B1 6/2001 Wall  
6,268,343 B1 7/2001 Knudsen et al.  
6,274,553 B1 8/2001 Furuya  
6,284,727 B1 9/2001 Kim et al.  
6,380,357 B2 4/2002 Hermeling et al.  
6,384,016 B1\* 5/2002 Kaarsholm ..... 514/11.7  
6,440,930 B1\* 8/2002 Rinella, Jr. .... 424/10.1  
6,444,788 B1 9/2002 Staby  
6,569,832 B1 5/2003 Knudsen et al.  
6,573,237 B2\* 6/2003 Rinella, Jr. .... 514/9.9  
6,586,399 B1 7/2003 Drucker et al.  
6,844,321 B2 1/2005 Arentsen  
7,022,674 B2\* 4/2006 DeFelippis et al. .... 514/5.9  
7,049,284 B2 5/2006 Drucker et al.  
7,056,886 B2 6/2006 Isaacs  
7,112,567 B2 9/2006 Bridon et al.  
7,202,213 B2 4/2007 Mogensen et al.  
7,226,990 B2 6/2007 Knudsen et al.  
7,238,663 B2 7/2007 DeFelippis et al.  
7,273,921 B2 9/2007 Dunweber et al.  
7,595,293 B2 9/2009 Englund et al.  
7,833,531 B2\* 11/2010 O'Neil et al. .... 424/178.1  
8,071,103 B2\* 12/2011 O'Neil et al. .... 424/178.1  
8,114,833 B2\* 2/2012 Pedersen et al.  
2001/0014666 A1 8/2001 Hermeling et al.  
2001/0027180 A1 10/2001 Isaacs  
2002/0151467 A1 10/2002 Leung  
2003/0060412 A1 3/2003 Prouty et al.  
2003/0069182 A1 4/2003 Rinella  
2003/0119734 A1 6/2003 Flink et al.  
2003/0158101 A1 8/2003 Drucker  
2003/0207802 A1 11/2003 DeFelippis et al.  
2003/0220243 A1 11/2003 Glaesner et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA 2306024 4/1999  
CA 2527743 12/2004

(Continued)

OTHER PUBLICATIONS

Buffers from Ruzin, 1999, Plant Microtechnique and Microscopy, accessed online on Dec. 24, 2013 at <http://microscopy.berkeley.edu/Resources/instruction/buffers.html>, pp. 1-6.\*  
D.E. Smilek et al., Proc Natl Acad Sci USA, vol. 88, pp. 9633-9637, (1991).  
D. Voet and J.G. Voet, Biochem, 2<sup>nd</sup> Ed., pp. 235-241 (1995).  
H.J.C. Berendsen, Science, vol. 282, pp. 642-643 (1998).  
Rudinger, In: Peptide Hormones, JA Parsons, Ed., pp. 1-7 (1976).  
Sigma, [http://www.sigma-genosys.com/peptide\\_design.asp](http://www.sigma-genosys.com/peptide_design.asp) (accessed Dec. 16, 2004).  
W.S. Messer, Vasopressin and Oxytocin, <http://www.neurosci.pharm.utoldeo.edu/MBC3320/vasopressin.htm>, accessed online Feb. 27, 2006.

(Continued)

*Primary Examiner* — Marcela M Cordero Garcia  
(74) *Attorney, Agent, or Firm* — Rosemarie R. Wilk-Orescan

(57) **ABSTRACT**

Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof.

(56)

References Cited

U.S. PATENT DOCUMENTS

2003/0220255 A1 11/2003 Knudsen et al.  
 2004/0156835 A1 8/2004 Imoto et al.  
 2004/0248782 A1 12/2004 Bridon et al.  
 2006/0084605 A1 4/2006 Englund et al.  
 2006/0287221 A1 12/2006 Knudsen et al.  
 2009/0011976 A1 1/2009 Ludvigsen et al.

FOREIGN PATENT DOCUMENTS

CN 1376166 10/2002  
 EP 0431679 11/1990  
 EP 0438767 12/1990  
 EP 699687 8/1995  
 EP 0708179 A2 4/1996  
 EP 747390 12/1996  
 EP 0923159 6/1999  
 EP 1329462 10/2001  
 EP 1424077 5/2002  
 EP 1344533 9/2003  
 EP 1396499 3/2004  
 EP 722492 3/2005  
 JP 10101696 4/1998  
 JP 2000-510813 8/2000  
 JP 2001-525371 12/2001  
 JP 2002-504908 2/2002  
 JP 2002-508332 3/2002  
 JP 2002-524514 8/2002  
 JP 2002-532557 10/2002  
 JP 2003519195 6/2003  
 JP 2004-518756 6/2004  
 PA 200101010 6/2001  
 RU 2180218 3/2002  
 WO WO9000200 1/1990  
 WO WO9219260 11/1992  
 WO 9318785 9/1993  
 WO WO9323010 11/1993  
 WO WO9522560 2/1995  
 WO 9505848 3/1995  
 WO WO95/10605 4/1995  
 WO WO9513825 5/1995  
 WO WO 96/20005 7/1996  
 WO 9624369 8/1996  
 WO WO9638469 12/1996  
 WO 98/00152 A1 1/1998  
 WO WO 98/08871 3/1998  
 WO WO9831386 7/1998  
 WO 9856406 12/1998  
 WO WO9916417 4/1999  
 WO WO99/21889 5/1999  
 WO WO 99/29336 6/1999  
 WO WO 99/30731 6/1999  
 WO WO 99/43341 9/1999  
 WO WO 99/43706 9/1999  
 WO WO 99/43707 9/1999  
 WO WO 00/15224 3/2000  
 WO WO 00/37098 6/2000  
 WO WO0037098 6/2000  
 WO WO 00/41546 7/2000  
 WO WO 00/55119 9/2000  
 WO WO 01/00223 1/2001  
 WO WO 01/43762 6/2001  
 WO 0151071 7/2001  
 WO WO 01/49314 7/2001  
 WO WO01/52937 7/2001  
 WO WO 01/55213 8/2001  
 WO WO 01/77141 10/2001  
 WO WO02067989 1/2002  
 WO 0247716 6/2002  
 WO WO 02/47715 6/2002  
 WO WO 02/48183 6/2002  
 WO 0298445 12/2002  
 WO WO 03/002136 1/2003

WO 03035099 5/2003  
 WO WO 03/035099 5/2003  
 WO WO 2004/029076 4/2004  
 WO WO2004105781 12/2004  
 WO WO 2005/000222 1/2005  
 WO WO2005/046716 5/2005  
 WO WO 2006/025882 3/2006

OTHER PUBLICATIONS

G.F. Stamper et al., "Accelerated Stability Testing of Proteins and Peptides: pH-Stability Profile of Insulinotropin Using Traditional Arrhenius and Non-Linear Fitting Analysis", Drug Development and Industrial Pharmacy, 1995, vol. 21, No. 13, pp. 1503-1511.  
 H. Qi et al., "Stability and Stabilization of Insulinotropin in a Dextran Formulation", PDA Journal of Pharmaceutical Science & Technology, vol. 49, No. 6, Nov.-Dec. 1995, pp. 289-293.  
 European Pharmacopoeia, 2007, vol. 1, p. 730, Council of Europe-Strasbourg.  
 Non-Final Office Action mailed Dec. 9, 2009 in U.S. Appl. No. 12/184,531 filed Aug. 1, 2008 by Juul-Mortensen.  
 Bailey et al. The Kinetics of Enzyme-Catalysed Reactions Biochemical Engineering Fundamentals, 2<sup>nd</sup> Ed., pp. 129-148 (1986).  
 Blundell, T.L., Lefévre P.J. (Ed), 1983, Vol. 66, p. 37-55.  
 S.E. Bondos & A. Bicknell, Detection and Prevention of Protein Aggregation Before During and After Purification, Analytical Biochemistry, 2003, 223-231, vol. 316, Academic Press.  
 Council of Europe—Strasbourg, European Pharmacopoeia, 2007, vol. 1, p. 730.  
 Entry for Glycerin in Drugs.Com (www.drugs.com/ppa/glycerin-glycerol.html), Printed Aug. 4, 2009.  
 Malendowicz, L.K. et al., "Preproglucagon Derived Peptides and Thyrotropin (TSH) Secretion in the Rat: Robust and Sustained Lowering of Blood TSH Levels in Extentin-4 Injected Animals", International Journal of Molecular Medicine, vol. 10, p. 327-331 (2002).  
 Senderoff, R.I. et al. Consideration of Conformational Transitions and Racemization During Process Development of Recombinant Glucagon-Like Peptide-1, Journal of Pharmaceutical Sciences, 1998, 183-189, vol. 87—No. 2, American Chemical Society & American Pharm. Assc.  
 Tsoka et al, Selective Flocculation Ands Precipitation for the Improvement of Virus-Like Particle Recovery From Yeast Homogenate, Biotechnol Prog. vol. 16(4), pp. 661-667 (2000).  
 Shinotesuto, Patentabstracts of Japan for JP10101696.  
 Brittain, Harry G., Buffers, Buffering Agents, and Ionic Equilibria, Encyclopedia of Pharmaceutical Technology, p. 385, 2007.  
 Non-Final Office Action in U.S. Appl. No. 11/290,634, filed Nov. 30, 2005, Inventors: Juul-Mortensen et al. Sent Jun. 30, 2008.  
 Non-Final Office Action in U.S. Appl. No. 11/290,634, filed Nov. 30, 2005, Inventors: Juul-Mortensen et al. Sent Nov. 9, 2007.  
 Non-Final Office Action in U.S. Appl. No. 11/290,635, filed Nov. 30, 2005, Inventors: Juul-Mortensen et al. Sent Feb. 2, 2007.  
 Non-Final Office Action in U.S. Appl. No. 11/290,635, filed Nov. 30, 2005, Inventors: Juul-Mortensen et al. Sent Feb. 2, 2007.  
 Non-Final Office Action in U.S. Appl. No. 11/365,274, filed Mar. 1, 2006, Inventors: Schlein et al. Sent Aug. 20, 2007.  
 Non-Final Office Action in U.S. Appl. No. 11/365,274, filed Mar. 1, 2006, Inventors: Schlein et al. Sent Feb. 5, 2007.  
 Non-Final Office Action in U.S. Appl. No. 11/365,274, filed Mar. 1, 2006, Inventors: Schlein et al. Sent Jan. 28, 2009.  
 Non-Final Office Action in U.S. Appl. No. 11/435,977, filed May 17, 2006, Inventors: Pedersen et al. Sent Dec. 2, 2008.  
 Non-Final Office Action in U.S. Appl. No. 10/185,923, filed Jun. 27, 2002, Inventors: Flink et al. Sent Mar. 10, 2006.  
 Non-Final Office Action in U.S. Appl. No. 10/185,923, filed June 27, 2002, Inventors: Flink et al. Sent Mar. 10, 2006.  
 Non-Final Office Action in U.S. Appl. No. 11/786,095, filed Apr. 11, 2007, Inventors: Flink et al. Sent Feb. 24, 2009.  
 Non-Final Office Action in U.S. Appl. No. 12/343,722, filed Dec. 24, 2008, Inventors: Flink et al. Sent May 22, 2009.  
 Final Office Action in U.S. Appl. No. 11/290,635, filed Nov. 30, 2005, Inventors: Juul-Mortensen et al. Sent Sep. 5, 2007.

(56)

**References Cited**

## OTHER PUBLICATIONS

- Final Office Action in U.S. Appl. No. 11/365,274, filed Mar. 1, 2006, Inventors: Schlein et al. Sent Aug. 12, 2009.
- Final Office Action in U.S. Appl. No. 11/435,977, filed May 17, 2006, Inventors: Pedersen et al. Sent Jun. 25, 2009.
- Final Office Action in U.S. Appl. No. 10/185,923, filed Jun. 27, 2002, Inventors: Flink et al. Sent Dec. 12, 2006.
- Final Office Action in U.S. Appl. No. 10/185,923, filed Jun. 27, 2002, Inventors: Flink et al. Sent June 14, 2005.
- Final Office Action in U.S. Appl. No. 10/185,923, filed Jun. 27, 2002, Inventors: Flink et al. Sent June 30, 2008.
- Final Office Action in U.S. Appl. No. 11/786,095, filed Apr. 11, 2007, Inventors: Flink et al. Sent Nov. 24, 2009.
- Eli Lilly & Co., Humalog Lispro Injection, USP Product Information.
- European Pharmacopoeia, 3RD Edition, 2.2.3, 1997, pp. 17-8, Council of Europe-Strasbourg.
- Frokjaer & Hovgaard, Pharmaceutical Formulation Development of, 2000, pp. 145-148 & 150-151.
- Further Experimental Data Dated Jun. 22, 2009.
- Gonzales, Johnny C., Declaration of (Including Curriculum Vita) Dated Nov. 1, 2010.
- Knudsen, L.B. et al., Potent Derivatives of Glucagon-Like Peptide-1, *Journal of Medicinal Chemistry*, 2000, vol. 43, pp. 1664-1669.
- Kristensen, H.G., *Almen Farmaci*, 2000, pp. 273-274, 281.
- Lund, Walter, Editor, *The Pharmaceutical Codex*, 12th Edition, 1994, The Pharmaceutical Press, London, pp. 98-99.
- Mack Publishing Co., *Remington's Pharmaceutical Sciences*, 16th Edition, 1980, Pt. 79, p. 1406.
- Mack Publishing Co., *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 84, pp. 1545-1550.
- Martin A. et al., *Physical Pharmacy; Physical Chemical Principles in the Pharmaceutical Sciences*, 1983, 3rd Edition, pp. 222-225.
- Sigma Product Information on Gly-Gly Buffer Dated Mar. 16, 2010.
- United States Pharmacopoeia, 24th Edition, 1999, pp. 1977-1978.
- Villaneuva\_Penacarril, M.L., Potent Glycogenic Effect of GLP-1(7-36) Amide in Rat Skeletal Muscle, *Diabetologia*, 1994, vol. 37, pp. 1163-1166.
- Wang & Hansen, *Journal of Parenteral Science & Technology*, 1988, vol. 42, pp. 4-26.
- Wang et al., *Aggregation of Therapeutic Proteins*, 2010, p. 241.
- Weinstein, Sharon, *Plumer's Principles & Practice of Intravenous*, 2006, vol. 8 (8), pp. 124-128.
- Duma et al., *Pharmaceutical Dosage Forms: Parenteral Medications*, vol. 1, 2nd Edition, p. 20.
- Stenesh, J., *Foundation of Biochemistry II Biomolecules*, 1998, pp. 67-69.
- Chou, J. Z. et al., *Journal of Pharmaceutical Sciences*, a Radioimmunoassay for LY315902, an Analog of Glucagon-Like Insulinotropic Peptide, and Its Application in the Study of Canine Pharmacokinetics, vol. 86(7), pp. 768-773 (1997).
- <http://www.copewithcytokines.de/cope.cgi?key=insulintropin;> (Host Ibelgauff's COPE: Cytokines & Cells Online pathfinder Encyclopedia; insulintropin), 1987.
- <http://www.copewithcytokines.de/cope.cgi?key=GLP%2d;> (Host Ibelgauff's COPE: Cytokines & Cells Online Pathfinder Encyclopedia; GLP-1), 1987.
- <http://www.fermantas.com/techinfo/appendix/appendixtables1.htm>, 'Temperature Dependence of the Ph for Commonly Used Buffers' + 'Temperature Dependence of the Ph of 50 mm Tris-HCL Solutions', 1966.
- Larsen, P.J. et al., Systemic Administration of the Logn Acting GLP-1, *Diabetes*, 2000 vol. 50, pp. 2530-2539.
- N. Good et al., "Hydrogen Ion Buffers for Biological Research", *Biochemistry*, 1966, vol. 5, No. 2, pp. 467-477.
- <http://www.sigmaaldrich.com/life-science/metabolomics/enzyme-explorer/learning-center/assay-library/assays-by-enzyme-name-ii.html#%20G%>, Enzymatic Assay of Glucose-6-Phosphate obtained from the Sigma Aldrich website, 1996.
- Singh, S. et al. *AAPS Pharmscitech*, vol. 4(3), pp. 334-342 (2003).
- Skovgaard et al., "Using Evolutionary Information and Ancestral Sequences to Understand the Sequence-Function Relationship in GLP-1 Agonists," *J. Mol. Bio.*, 2006, vol. 363, pp. 977-988.
- Pridal et al., "Absorption of Glucagon-Like Peptide-1 Can Be Protracted by Zinc or Protamine", *International Journal of Pharmaceutics*, 1996, vol. 136, pp. 53-59.

\* cited by examiner

1

## STABLE FORMULATION OF MODIFIED GLP-1

### CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 11/786,095 filed on Apr. 11, 2007, which is a continuation of U.S. application Ser. No. 10/185,923 filed on Jun. 27, 2002 and claims priority under 35 U.S.C. 119 of Danish Application No. PA 2001 01010 filed Jun. 28, 2001; Danish Application No. PA 2001 01011 filed Jun. 28, 2001; Danish Application No. PA 2001 01052 filed Jul. 4, 2001; Danish Application No. PA 2001 01053 filed Jul. 4, 2001; and Danish Application No. PA 2002 00093 filed Jan. 18, 2002; and U.S. Provisional Applications No. 60/308,325 filed Jul. 27, 2001 and 60/308,297 filed Jul. 27, 2001, the contents of which are fully incorporated herein by reference.

### FIELD OF THE INVENTION

The present invention relates to pharmaceutical formulations comprising GLP-1 compounds, uses thereof and methods for preparing said formulations.

### BACKGROUND OF THE INVENTION

Peptides are widely used in medical practice, and since they can be produced by recombinant DNA technology it can be expected that their importance will increase also in the years to come.

The hormones regulating insulin secretion belong to the so-called enteroinsular axis, designating a group of hormones, released from the gastrointestinal mucosa in response to the presence and absorption of nutrients in the gut, which promote an early and potentiated release of insulin. The enhancing effect on insulin secretion, the so-called incretin effect, is probably essential for a normal glucose tolerance. Many of the gastrointestinal hormones, including gastrin and secretin (cholecystokinin is not insulinotropic in man), are insulinotropic, but the only physiologically important ones, those that are responsible for the incretin effect, are the glucose-dependent insulinotropic polypeptide, GIP, and glucagon-like peptide-1 (GLP-1). Because of its insulinotropic effect, GIP, isolated in 1973 immediately attracted considerable interest among diabetologists. However, numerous investigations carried out during the following years clearly indicated that a defective secretion of GIP was not involved in the pathogenesis of insulin dependent diabetes mellitus (IDDM) or non insulin-dependent diabetes mellitus (NIDDM). Furthermore, as an insulinotropic hormone, GIP was found to be almost ineffective in NIDDM. The other incretin hormone, GLP-1 is the most potent insulinotropic substance known. Unlike GIP, it is surprisingly effective in stimulating insulin secretion in NIDDM patients. In addition, and in contrast to the other insulinotropic hormones (perhaps with the exception of secretin) it also potently inhibits glucagon secretion. Because of these actions it has pronounced blood glucose lowering effects particularly in patients with NIDDM.

GLP-1, a product of the proglucagon, is one of the youngest members of the secretin-VIP family of peptides, but is already established as an important gut hormone with regulatory function in glucose metabolism and gastrointestinal secretion and metabolism. The glucagon gene is processed

2

tion of 1) glucagon itself, occupying positions 33-61 of proglucagon (PG); 2) an N-terminal peptide of 30 amino acids (PG (1-30)) often called glicentin-related pancreatic peptide, GRPP; 3) a hexapeptide corresponding to PG (64-69); 4) and, finally, the so-called major proglucagon fragment (PG (72-158)), in which the two glucagon-like sequences are buried. Glucagon seems to be the only biologically active product. In contrast, in the intestinal mucosa, it is glucagon that is buried in a larger molecule, while the two glucagon-like peptides are formed separately.

While much attention has been focused on the pharmacological properties of acylated GLP-1 compounds, hitherto little is known about their physico-chemical and solution structural properties. Such knowledge is a prerequisite for rational handling during e.g. production, purification and formulation work and is eventually important for understanding of the structural basis for the protraction mechanism.

It is an important technical challenge to ensure prolonged stability during storage (shelf life) of many protein based drug products due to the inherent lability of macromolecules. Hence, proteins are sensitive to both chemical and physical degradation unlike many small molecules. Chemical degradation involves covalent bonds, such as hydrolysis, racemization, oxidation or crosslinking. Physical degradation involves conformational changes relative to the native structure, which includes loss of higher order structure, aggregation, precipitation or adsorption to surfaces. GLP-1 is known to be prone to instability due to aggregation. Both degradation pathways may ultimately lead to loss of biological activity of the protein drug.

GLP-1 and analogues of GLP-1 and fragments thereof are potentially useful i.a. in the treatment of type 1 and type 2 diabetes. However, solubility limitations and the low stability against the actions of endogenous diaminopeptidyl peptidase limits the usefulness of these compounds, and thus there still is a need for improvements in this field.

In WO 99/43341 are disclosed certain pharmaceutical formulations comprising GLP-1 having a lipophilic substituent. All of the disclosed formulations are maintained at pH 7.4.

In WO 00/37098 are disclosed shelf-stable formulations comprising GLP-1, a preservative, and a tonicity modifier, at pH 8.2 to 8.8.

Human GLP-1 is a 37 amino acid residue peptide originating from proglucagon which is synthesised i.a. in the L-cells in the distal ileum, in the pancreas and in the brain. Processing of proglucagon to give GLP-1(7-36)amide, GLP-1(7-37) and GLP-2 occurs mainly in the L-cells. A simple system is used to describe fragments and analogues of this peptide. Thus, for example, Val<sup>8</sup>-GLP-1(7-37) (or Val<sup>8</sup>GLP-1(7-37)) designates a fragment of GLP-1 formally derived from GLP-1 by deleting the amino acid residues Nos. 1 to 6 and substituting the naturally occurring amino acid residue in position 8 (Ala) by Val. Similarly, Lys<sup>34</sup>(N<sup>ε</sup>-tetradecanoyl)-GLP-1(7-37) designates GLP-1(7-37) wherein the  $\epsilon$ -amino group of the Lys residue in position 34 has been tetradecanoylated. For convenience the amino acid sequence of GLP-1 (7-37) is given below, wherein the N-terminal His is no. 7 and the C-terminal Gly is no. 37:

(SEQ ID NO.: 1)

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-  
Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-



Where reference in this text is made to C-terminally extended GLP-1 analogues, the amino acid residue in position 38 is Arg unless otherwise indicated, the optional amino acid residue in position 39 is also Arg unless otherwise indicated and the optional amino acid residue in position 40 is Asp unless otherwise indicated. Also, if a C-terminally extended analogue extends to position 41, 42, 43, 44 or 45, the amino acid sequence of this extension is as in the corresponding sequence in human preproglucagon unless otherwise indicated.

#### SUMMARY OF THE INVENTION

We have discovered that certain modified GLP-1 or analogues thereof when formulated in aqueous solution together with a buffer, are physically stable at high concentrations of the modified GLP-1 or analogues thereof, when kept in the pH range from about 7 to about 10. The present formulations are physically stable within a given shelf life period at the recommended storage temperature (typically 2-3 years at 2-8° C.). Furthermore, the present formulations are physically stable during in-use (typically 1 month at accelerated temperatures e.g. 25° C. or 37° C.). The formulations of the invention are also chemically stable thus rendering them shelf-stable and suitable for invasive (eg. injection, subcutaneous injection, intramuscular, intravenous or infusion) as well as non-invasive (eg nasal or pulmonary, transdermal or transmucosal e.g. buccal) means of administration. When the inventive formulation comprising a GLP-1 compound was compared to the same formulation comprising GLP-1(7-37) substituted for the GLP-1 compound, the physical stability was increased considerably, and typically the shelf-life was increased from a few seconds to several months in the tests used.

One object of the present invention is to provide a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10;

Another object of the present invention is to provide a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.

In one aspect of the invention the formulation contains a GLP-1 compound in a concentration from 1 mg/ml to 100 mg/ml.

In another aspect of the invention the formulation has a pH from 7.5 to 10.

In one embodiment the GLP-1 compound is Arg<sup>34</sup>, Lys<sup>26</sup> (N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37).

#### DESCRIPTION OF THE INVENTION

In one aspect the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent

peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10;

provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent.

In another aspect the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10;

provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent.

In a further aspect the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10.

In a further aspect the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10.

In a further aspect the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.

In a further aspect the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.

In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10.

In a further aspect the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.